Liver Cancer

Partnership Combines Drug Delivery Systems

Published in Cancer Weekly, December 19th, 2000

FeRx Inc., announced November 28, 2000, a partnership with Elan Corporation, plc, to develop, manufacture, and commercialize FeRx's lead product, MTC-DOX, currently in Phase I/II clinical trials in the United States, for the treatment of primary liver cancer.

"The combination of FeRx's novel MTC drug delivery system with Elan's drug delivery technology, and emerging emphasis in oncology provides an excellent match for accelerating clinical development and realizing the potential of our MTC technology," said Jacqueline Johnson, PhD, FeRx.

FeRx's proprietary Magnetic Targeted Carriers (MTCs) are microparticles, composed of elemental iron and activated...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-12-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry